Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276415 | 0.89 | EGFR (0.44) | EGFRERBB2ALDH1A1MAPTHPGD | |
| SCHEMBL742983 | 0.87 | EGFR (0.46) | EGFRERBB2ALDH1A1NPC1HPGD | |
| SCHEMBL744320 | 0.86 | FGFR1 (0.42) | ALDH1A1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL762162 | 0.86 | FGFR1 (0.33) | ALDH1A1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL275481 | 0.85 | MAPT (0.54) | EGFRERBB2MAPTSMN1; SMN2 | |
| SCHEMBL13892299 | 0.84 | FGFR1 (0.37) | EGFRERBB2ALDH1A1MAPTLMNA | |
| SCHEMBL276526 | 0.81 | MAP2K1 (0.46) | EGFRERBB2ALDH1A1MAPTLMNA | |
| SCHEMBL742979 | 0.80 | LMNA (0.39) | MAPTLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL276495 | 0.79 | EGFR (0.46) | EGFRERBB2KDRMAPK14FGFR1 | |
| Hydrochloric Acid SCHEMBL275478 | 0.79 | EGFR (0.45) | EGFRERBB2KDRMAPK14FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | EGFR 1566/4885ERBB2 838/4885POLB 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.